CSBio CSBio

X
[{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women's & Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LUCA Science"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","amount":"$30.3 million","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Raises \u00a53.86 Billion ($30.3 Million) in Oversubscribed Series B Financing","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LUCA Science"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Anti-IL-8 Recycling Antibody AMY109, Improves Inflammation and Fibrosis in Endometriosis in an Industry-Government-Academia Non-Clinical Study Published in Science Translational Medicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Chugai Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            AMY109 is a novel therapeutic antibody with a recycling function that binds to IL-8 (an inflammatory cytokine) and improves inflammation and fibrosis in endometriosis.

            Lead Product(s): AMY109

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: AMY109

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from financing will also be used to establish a robust manufacturing system based on its proprietary Mitochondrial Isolation Technology platform, a novel method for intact, shelf-stable and highly functional isolated mitochondria as a biopharmaceutical agent.

            Lead Product(s): Mitochondrial-based Therapy

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Fast Track Initiative

            Deal Size: $30.3 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This collaboration was formed in order to realise this solution and seeks to address this by specifically delivering therapeutics to the placenta, combining unique technology developed at LUCA Science with extensive placental research experience at the University of Oxford.

            Lead Product(s): Mitochondrial therapy

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: University of Oxford

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY